<i>LuciA-15</i> - a real-world prospective study of PARP inhibitors for the treatment of patients with HER-2 negative metastatic breast cancer with germline and/or somatic mutation of BRCA genes or homologous recombination repair related genes.

Ecancermedicalscience · 2023 · PMC10898875 · PMID 38414929

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a negative trendno p-value reported

Analysing in isolation the effect of the use or not of PbCT prior to the start of PARPi had a negative trend in rwOS.

also in 2,315 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.